Replies to post #200878 on Biotech Values

[DewDiligence]

ABBV—I meant going "all in" is not right given the competitive situation.

I don’t understand your argument; from a return-on-investment standpoint, going “all in” by running a robust set of phase-3 trials for ABT-493/ABT-530 is almost certainly the right thing for ABBV to do.